Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 9, 2009 Brian Orelli	Alnylam Holds Hands With a New Fella Is big pharma turning up its nose at RNAi drugs?
The Motley Fool June 9, 2009 Brian Orelli	Alnylam Lays Down a Sacrifice Bunt RNAi is still an unproven technology, and there's plenty of chances for it to strike out.
The Motley Fool November 30, 2010 Brian Orelli	RNAi Is On Sale The novel technology looks more promising at these prices.
The Motley Fool May 18, 2007 Mike Havrilla	Ample Opportunities for Alnylam The biotech's RNAi pipeline and cutting-edge technology make it a prime takeover candidate. Investors, take note.
The Motley Fool February 28, 2011 Brian D. Pacampara	Next-Generation Drug Technologies Battle It Out Alnylam and Sangamo BioSciences have different ways to manipulate proteins to fight disease.
The Motley Fool August 31, 2010 Brian Orelli	A Mostly Meaningless FDA Rejection The Food and Drug Administration sends AstraZeneca back to the drawing board for the second time when it rejected motavizumab, the drugmaker's newest treatment for respiratory syncytial virus.
The Motley Fool July 11, 2007 Brian Orelli	Everybody Loves RNAi Roche is the latest firm to (over)pay for the hottest new drug technology. Alnylam announced that it licensed some of its intellectual property to Roche for $331 million. Investors, take note.
The Motley Fool August 1, 2007 Brian Orelli	RNAi Gets Pumped Up Is a collaboration between RNAi expert Alnylam Pharmaceuticals and medical-device maker Medtronic something investors can endorse?
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
The Motley Fool September 24, 2010 Brian Orelli	So Long and Thanks for All the Drug Candidates Alnylam and Novartis end their five-year partnership.
The Motley Fool April 29, 2011 Brian Orelli	Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya.
The Motley Fool May 28, 2008 Brian Orelli	A Partnership of Habitual Deal Makers A partnership between these two companies gives Alnylam another $150 million to pad its coffers with and Takeda a call option on an unproven but promising set of drugs.
The Motley Fool September 24, 2009 Brian Orelli	Drugmakers' HIV Treatments Live On Companies that make HIV drugs could lose billions of dollars in revenue if an effective vaccine is developed. All drug-company investors need to keep an eye on up-and-coming drugs from competitors that could take market share.
The Motley Fool November 6, 2006 Ralph Casale	Validation for a Biotechnology Firm? How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals. With the recent run-up in share price due to the Merck offer for Sirna, investors should wait for a better price before speculating on Alnylam.
The Motley Fool October 27, 2010 Brian Orelli	Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan.
The Motley Fool September 20, 2007 Brian Orelli	A Pharma Divorce, and Good Riddance Merck and Alnylam call it quits. The only real question is why the two didn't end the partnership months ago. What will it mean to investors?
The Motley Fool September 29, 2011 Brian Orelli	Are HIV Drugmakers Doomed? Generics are a bigger threat than Sangamo for now.
The Motley Fool July 21, 2010 Brian Orelli	Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive.
Chemistry World July 2010 Hayley Birch	Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool September 28, 2007 Brian Orelli	RNAi Doesn't Kill Mice After All From Merck, to AstraZeneca, to Novartis, big pharma continues to pump hundreds of millions of dollars into unproven RNAi technology. Investors, take note.
The Motley Fool July 30, 2007 Brian Orelli	Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug.
The Motley Fool March 24, 2008 Brian Orelli	Alnylam Authorizes Again The pharmaceutical's latest patent-licensing deal won't be immediately lucrative.
The Motley Fool February 9, 2006 Jason Mac Gurn	RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals...
Bio-IT World November 2006 Kevin Davies	Merck's $1.1 Billion Bet on RNAi As if the 2006 Nobel Prize in Medicine or Physiology wasn't validation enough, Merck's acquisition of biotech firm Sirna for $1.1 billion last month offered evidence of the commercial implications of RNA interference gene-silencing technology.
BusinessWeek February 26, 2007 Gene G. Marcial	CytRx Can 'Silence' Genes That Cause Disease Since October, shares of CytRx have more than doubled as investors zeroed in on its RNA interference technology that targets diabetes, obesity, and ALS.
The Motley Fool March 25, 2011 Brian Orelli	Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science.
Managed Care January 2002 William Silverman	A Health Care Management Company's Experience with Palivizumab On June 19, 1998, the Food and Drug Administration licensed palivizumab, as the first monoclonal antibody introduced into clinical practice for the prevention of an infectious disease, respiratory syncytial virus (RSV) disease...
Bio-IT World December 15, 2004 Zachary Zimmerman	Silence Is Golden Life Science Insights believes that RNAi therapeutics will dramatically affect the pharmaceutical and healthcare industries, becoming the next major class of therapeutics, joining small molecules, proteins, and monoclonal antibodies.
American Family Physician January 15, 2004 Robert Steiner	Treating Acute Bronchiolitis Associated with RSV Treatment for infants with bronchiolitis caused by respiratory syncytial virus (RSV) includes supplemental oxygen, nasal suctioning, fluids to prevent dehydration, and other supportive therapies.
Managed Care September 2003 William Silverman	Is Selective Use of Palivizumab Appropriate in Premature Infants? In reference to the article in the May 2003 issue of Managed Care entitled "A Health Care Management Company's Experience with Palivizumab," the assertions made by William Silverman, MD, in that article deserve comment.
The Motley Fool October 5, 2006 Ralph Casale	RNAi: Nobel Prize-Winning Biotechnology While drugs based on RNAi knockdown technology may have the potential to become the next big thing in biotechnology, they are still a long way from becoming FDA-approved marketable entities. But it's never too soon to start keeping an eye on the future. Investors, take note.
The Motley Fool August 15, 2006 Ralph Casale	Sirna Battles Genes Gone Bad Pharmaceutical start-up Sirna Therapeutics tests drugs to silence rogue genes. Investors, while drugs based on RNA interference may have the potential to become the next big thing in biotechnology, they're still a long, long way from becoming FDA-approved, marketable entities.
American Family Physician August 15, 2003	West Nile Virus What is West Nile virus?... How do people get infected with West Nile virus?... What are the symptoms of West Nile virus infection?... Who is at risk for infection with West Nile virus?... Is there a treatment for West Nile virus infection?... etc.
The Motley Fool January 31, 2011 Brian Orelli	Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet.
Chemistry World August 7, 2008 Simon Hadlington	RNA stops HIV in its tracks Scientists have successfully used a biochemical Trojan horse to smuggle killer sequences of RNA into immune cells to mug invading HIV, stopping infection in its tracks
Pharmaceutical Executive October 1, 2008	The other half of an HIV mystery is solved When HIV infects a human immune cell, which of the cell's own genes play a role?
The Motley Fool November 14, 2008 Brian Orelli	Gravy or Turkey From the FDA? Johnson & Johnson, Genzyme, and AstraZeneca should be made aware of their FDA fate over the next few weeks.
Nursing June 2010 Daniel A. Hussar	New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs.
Nursing June 2011 Daniel A. Hussar	New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis.
Bio-IT World December 15, 2004 Nancy Weil	Running Interference The revolution in RNA interference has galvanized basic research. Now, some biopharmas are pushing the technology from the laboratory to the clinic.
Managed Care November 2003 Thomas Morrow	Making Sense of Antisense and Interference Treatments that interfere with protein synthesis at the cellular level will soon be debated in medical policy committee meetings.
Bio-IT World December 15, 2004 David A. Bumcrot	Identifying RNAi Drug Candidates Breakthroughs in understanding RNA's extensive role in essential cellular processes have opened up the potential for a whole new class of drugs based on RNAi.
The Motley Fool December 1, 2008 Brian Orelli	It's Wait Until Next Year for These Drugmakers Drugs from AstraZeneca and Eli Lilly face delays because of the FDA. Both plan to resubmit their applications for approval in the first half of next year, but the delays likely will have different effects on the companies.
AskMen.com Jacob Franek	Future Cures Almost every disease known to man is under constant research and we can hardly go a day without hearing about some advancement or another. Here are a few diseases for which future cures could be looming on the horizon.
Pharmaceutical Executive July 30, 2007	Tomorrow's Drugs A look at the seven top therapies and technologies vying to deliver the next generation of drugs.
Chemistry World October 2, 2006 Bea Perks	RNAi Pioneers Win Nobel Prize for Medicine Molecular biologists Andrew Fire and Craig Mello have been awarded this year's Nobel prize in physiology or medicine for their discovery of RNA interference.
The Motley Fool November 13, 2006 Jack Uldrich	Arrowhead: A Long-Term RNAi Play? Its majority stake in Calando Pharmaceuticals could pay dividends. Investors would be wise to continue to watch this company and wait until clinical trials have advanced to a more mature stage before considering an investment.
Bio-IT World July 15, 2003 Malorye Branca	Silence Is Golden RNA interference's scientific, therapeutic, and economic potential is unquestionable, but some sticky questions still remain.
The Motley Fool November 18, 2010 Travis Hoium	Alnylam Pharmaceuticals Shares Plunged: What You Need to Know Roche Holding AG announced it would end its partnership with Tekmira Pharmaceuticals, dragging Alnylam down in the fray. This move affects research for RNAi therapeutics, a focus for Alnylam.